Clearly, there is room for improvement and in melanoma this is highlighted by the observed increase in progression-free survival in BRAF/MEK inhibitor combination therapies compared with BRAF inhibitor monotherapies (Larkin et al., 2014, Long et al., 2015). The gene discussed is MAP2K7; the disease is melanoma.